Boehringer-Ingelheim et al. v. Laurus Labs Limited et al.
Infringement action filed 7 Nov 2018 in the United States District Court for the District of Delaware and closed 18 May 2023, with 2 patents asserted. Recorded basis of termination: consent judgment.
Case record
- Patents involved
- US9949998B2US7579449B2
- Case no.
- 1:18-cv-01758
- Verdict cause
- Infringement action
- Court
- D. Del.
- Court level
- District Court
- Case region
- Delaware
- Chief judge
- None recorded
- Trial level
- First instance
- Filed – Closed
- 7 Nov 2018 – 18 May 2023
- Duration
- 1653 days
- Basis of termination
- Consent Judgment
- Products & marks
- Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture · Pharmaceutical composition, methods for treating and uses thereof
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Pharmaceutical composition, methods for treating and uses thereof
The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
- Legal status
- Active
- Granted
- 24 Apr 2018
- Earliest priority
- 26 Nov 2013
- Est. expiry
- 11 Dec 2034
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Classification
- A61K31/7034A61K31/7048A61K9/20A61K9/28
- Prosecution counsel
- VP, IP, LEGAL
- Examiner
- MCINTOSH, III, TRAVISS C
Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Glucopyranosyl-substituted benzene derivatives of general formula Iwhere the groups R1 to R6 as well as R7a, R7b, R7c are defined herein and the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
- Legal status
- Active
- Granted
- 25 Aug 2009
- Earliest priority
- 16 Mar 2004
- Est. expiry
- 1 Feb 2029
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- ECKHARDT, MATTHIAS · EICKELMANN, PETER · HIMMELSBACH, FRANK · BARSOUMIAN, EDWARD LEON · THOMAS, LEO
- Classification
- A61K31/70A61K31/351A61K31/7004C07H7/04A61P3/00C07D309/10C07H15/04C07H15/20C07H15/26
- Prosecution counsel
- VP, IP, LEGAL
- Examiner
- JIANG, SHAOJIA ANNA
Parties of record
Boehringer-Ingelheim
- Core tech
- A61K31/7034A61K31/7048A61K9/20A61K9/28
- Counsel
- Brian P. Egan · Jack B. Blumenfeld
- Firm
- Morris, Nichols, Arsht & Tunnell LLP
- Also named
- Boehringer Ingelheim Corporation · Boehringer Ingelheim International, GMBH
Laurus Labs Limited
- Core tech
- Not recorded
- Counsel
- Daniel J. Ritterbeck · Dennies Varughese, Pharm.D · Jeremy S. Cole · Joseph H. Kim · Nirav N. Desai
- Firm
- Flaster Greenburg PC
- Also named
- Laurus Generics Inc.
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Brian P. Egan | Boehringer-Ingelheim | Plaintiff |
| Jack B. Blumenfeld | Boehringer-Ingelheim | Plaintiff |
| Daniel J. Ritterbeck | Laurus Labs Limited | Defendant |
| Dennies Varughese, Pharm.D | Laurus Labs Limited | Defendant |
| Jeremy S. Cole | Laurus Labs Limited | Defendant |
| Joseph H. Kim | Laurus Labs Limited | Defendant |
| Nirav N. Desai | Laurus Labs Limited | Defendant |
Basis of termination
From the record · verbatim“Whereas Plaintiff Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals, Inc. (collEtively, “Boehringer”) Laurus Labs Ltd, and Laurus Generics, (collectively, “Latrus”) have agreed to terms and conditions representing a negotiated resolution of Civil Action Nos. 18-1758-CFC (D.Del) and 19-1 S96-CFC (D. Del.),which have consolidated With the matter, Civil Action No. 18.1689.CFC (D.Del.) WHEREAS the following definitions shall apply to this Consent Judgment: Patent” means U.s. patent No. 9,949.998; ‘637 Patent” means U.s. Patent 10,258.637; (iii) “Laurus ANDA Product” means the product described in Abbrevia New Drug Application N. 21242 t , including I O mg and 25 mg empagliflcrzin tablets as generic versions Of Jardiance. as existing on the Effective Date. as amended Or supplemented from time to time in the Ordinary course of business;”
Case 1:18-cv-01758 · D. Del. · closed 18 May 2023
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 1:18-cv-01758?
1:18-cv-01758 is a patent infringement action brought by Boehringer-Ingelheim against Laurus Labs Limited, filed on 7 Nov 2018 in the United States District Court for the District of Delaware. The case closed on 18 May 2023.
Which patents were asserted in 1:18-cv-01758?
US9949998B2 (“Pharmaceutical composition, methods for treating and uses thereof”), assigned to BOEHRINGER INGELHEIM INTERNATIONAL GMBH, currently active; US7579449B2 (“Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture”), assigned to BOEHRINGER INGELHEIM INTERNATIONAL GMBH, currently active. The record also lists Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture and Pharmaceutical composition, methods for treating and uses thereof.
How was case 1:18-cv-01758 terminated?
The recorded basis of termination is consent judgment. The termination text reads: “Whereas Plaintiff Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals, Inc. (collEtively, “Boehringer”) Laurus Labs Ltd, and Laurus Generics, (collectively, “Latrus”) have agreed to terms and conditions representing a negotiated resolution of Civil Action Nos. 18-1758-CFC (D.Del) and 19-1 S96-CFC (D. Del.),which have consolidated With the matter, Civil Action No. 18.1689.CFC (D.Del.) WHEREAS the following definitions shall apply to this Consent Judgment: Patent” means U.s. patent No. 9,949.998; ‘637 Patent” means U.s. Patent 10,258.637; (iii) “Laurus ANDA Product”
What does consent judgment mean?
A consent judgment is a judgment the parties agree to and the court enters. Unlike a bare dismissal it is enforceable as a judgment.
How long did case 1:18-cv-01758 take?
1653 calendar days, from filing on 7 Nov 2018 to closure on 18 May 2023.
Who were the attorneys and the judge in 1:18-cv-01758?
Brian P. Egan and Jack B. Blumenfeld are recorded as counsel for plaintiff Boehringer-Ingelheim. Daniel J. Ritterbeck, Dennies Varughese, Pharm.D, Jeremy S. Cole, Joseph H. Kim and Nirav N. Desai appear for defendant Laurus Labs.
Disclaimer. This page reproduces publicly available court docket data for case 1:18-cv-01758 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.